These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15272642)

  • 1. Increased fibrin specificity and reduced paradoxical thrombin activation of the combined thrombolytic regimen with reteplase and abciximab versus standard reteplase thrombolysis.
    Szabo S; Etzel D; Ehlers R; Walter T; Kazmaier S; Helber U; Beyer ME; Hoffmeister HM
    Drugs Exp Clin Res; 2004; 30(2):47-54. PubMed ID: 15272642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefical effects of reteplase in combination with abciximab: platelet/leukocyte interactions and coagulation system.
    Szabo S; Walter T; Etzel D; Ehlers R; Kazmaier S; Beyer ME; Hoffmeister HM
    Int J Clin Pharmacol Res; 2003; 23(2-3):37-40. PubMed ID: 15018016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
    Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
    J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
    Merlini PA; Repetto A; Andreoli AM; Ricci S; Lombardi A; Finardi A; Dipasquale G; Lamponi M; Mannucci PM; Ardissino D
    Am J Cardiol; 2004 Jan; 93(2):195-8. PubMed ID: 14715345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.
    Circulation; 2000 Jun; 101(24):2788-94. PubMed ID: 10859283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy).
    Cura FA; Roffi M; Pasca N; Wolski KE; Lincoff AM; Topol EJ; Lauer MS;
    Am J Cardiol; 2004 Oct; 94(7):859-63. PubMed ID: 15464665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab.
    Mukherjee D; Gurm H; Tang WH; Roffi M; Wolski K; Moliterno DJ; Guetta V; Ardissinio D; Bode C; Steg G; Lincoff AM; Topol EJ
    Am J Cardiol; 2002 Dec; 90(11):1198-203. PubMed ID: 12450598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.
    Kastrati A; Mehilli J; Schlotterbeck K; Dotzer F; Dirschinger J; Schmitt C; Nekolla SG; Seyfarth M; Martinoff S; Markwardt C; Clermont G; Gerbig HW; Leiss J; Schwaiger M; Schömig A;
    JAMA; 2004 Feb; 291(8):947-54. PubMed ID: 14982910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GUSTO V: combination drug treatment of acute myocardial infarction. Global Use of Strategies to Open Occluded Coronary Arteries.
    Askari AT; Lincoff AM
    Cleve Clin J Med; 2002 Jul; 69(7):554-60. PubMed ID: 12109639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries.
    Miller JM; Smalling R; Ohman EM; Bode C; Betriu A; Kleiman NS; Schildcrout JS; Bastos E; Topol EJ; Califf RM
    Am J Cardiol; 1999 Oct; 84(7):779-84. PubMed ID: 10513773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abciximab combined with half-dose reteplase has beneficial effects on inflammatory myocardial response in patients with myocardial infarction.
    Szabo S; Etzel D; Walter T; Kazmaier S; Oikonomopoulos T; Marx R; Hoffmeister HM
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):129-33. PubMed ID: 19786940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
    Ouriel K; Castaneda F; McNamara T; Swischuk J; Tepe G; Smith JJ; Clark J; Duda S
    J Vasc Interv Radiol; 2004 Mar; 15(3):229-38. PubMed ID: 15028807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
    Antman EM; Gibson CM; de Lemos JA; Giugliano RP; McCabe CH; Coussement P; Menown I; Nienaber CA; Rehders TC; Frey MJ; Van der Wieken R; Andresen D; Scherer J; Anderson K; Van de Werf F; Braunwald E
    Eur Heart J; 2000 Dec; 21(23):1944-53. PubMed ID: 11071800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
    Di Mario C; Bolognese L; Maillard L; Dudek D; Gambarati G; Manari A; Guiducci V; Patrizi G; Rusconi LC; Piovaccari G; Hibon AR; Belpomme V; Indolfi C; Olivari Z; Steffenino G; Zmudka K; Airoldi F; Panzarasa R; Flather M; Steg PG
    Am Heart J; 2004 Sep; 148(3):378-85. PubMed ID: 15389222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.
    Nakada MT; Montgomery MO; Nedelman MA; Guerrero JL; Cohen SA; Barnathan ES; Jordan RE
    J Vasc Interv Radiol; 2004 Feb; 15(2 Pt 1):169-76. PubMed ID: 14963184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
    Hoffmeister HM; Kastner C; Szabo S; Beyer ME; Helber U; Kazmaier S; Baumbach A; Wendel HP; Heller W
    Am J Cardiol; 2000 Aug; 86(3):263-8. PubMed ID: 10922430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
    Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS
    Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination pharmacotherapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa inhibition.
    Bush HS
    J Emerg Med; 2003 Nov; 25(4):421-6. PubMed ID: 14654184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.